黄羽棠，助理研究员。2021年获重庆医科大学药理学专业博士学位，同年进入重庆医科大学工作。主要从事恶性肿瘤分子靶向治疗药物耐药性发生机制及生物标志物研究。
联系方式：ythuang@cqmu.edu.cn
主要研究方向：
1.恶性肿瘤靶向药物耐药性发生机制以及生物标志物研究；
2.恶性肿瘤肿瘤微生物相关治疗新靶点研究。
代表性论文（#第一作者，*通讯作者）：
1.Yutang Huang#, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou,Lanxiang Wu* Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis. Medcomm. 2024
2.Huang Yutang#, Du Yan#, Zheng Yujie#, Wen Chunjie, Zou Hecun, Huang Jiafeng, Zhou Honghao, Zhao Hongbo*,Wu Lanxiang*. Ct-OATP1B3 promotes high-grade serous ovarian cancer metastasis by regulation of fatty acid beta-oxidation and oxidative phosphorylation. Cell Death Dis. 2022, 13:556.
3.Huang Yutang#, Dai Yi#, Wen Chunjie, He Shuai, Shi Jingjing, Zhao Dezhang,Wu Lanxiang*, Zhou Honghao. circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway. Mol Ther Nucleic Acids. 2020, 4;21:885-899.
